首页> Journal of clinical gastroenterology> Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response

导出原文传递

翻译打印收藏纠错

第一作者： Ma, Christopher

作者： Ma, Christopher ^[1] ; Huang, Vivian ; Fedorak, Darryl K. ; Kroeker, Karen I. ; Dieleman, Levinus A. ; Halloran, Brendan P. ; Fedorak, Richard N.

作者单位： Univ Alberta, Div Gastroenterol, Edmonton, AB T6G 2X8, Canada ^[1]

关键词 infliximab adalimumab ulcerative colitis dose escalation secondary loss of response

发布时间 2017-04-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of clinical gastroenterology

2015年49卷8期

675-682页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

Journal of clinical gastroenterology

2015年49卷8期

675-682页

检索历史清除

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response

Journal of clinical gastroenterology

相似文献

同项目论文

Journal of clinical gastroenterology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response

Journal of clinical gastroenterology

相似文献

同项目论文

Journal of clinical gastroenterology

相关期刊

检索历史清除